skip to content

Cambridge Immunology Network

 
Read more at: Four Cambridge researchers recognised in the 2022 Breakthrough Prizes

Four Cambridge researchers recognised in the 2022 Breakthrough Prizes

10 September 2021

Four University of Cambridge researchers – Professors Shankar Balasubramanian, David Klenerman, Suchitra Sebastian and Jack Thorne – have been recognised by the Breakthrough Prize Foundation in recognition of their outstanding achievements. Read the original article here>


Read more at: Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity

Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity

6 September 2021

Findings suggest infection control measures against variants will need to continue in the post-vaccination era. The Delta variant of SARS-CoV-2, which has become the dominant variant in countries including India and the UK, has most likely spread through its ability to evade neutralising antibodies and its increased...


Read more at: Patients with SARS-CoV-2 Delta variant were more likely to be admitted to hospital compared to patients with Alpha variant

Patients with SARS-CoV-2 Delta variant were more likely to be admitted to hospital compared to patients with Alpha variant

31 August 2021

Largest study to date analysing more than 40,000 COVID-19 cases finds a two-fold increased risk of hospitalisation from delta versus alpha variant infections. Read the original article here>


Read more at: Discovery of origin of oesophageal cancer cells highlights importance of screening for pre-cancerous Barrett’s oesophagus

Discovery of origin of oesophageal cancer cells highlights importance of screening for pre-cancerous Barrett’s oesophagus

12 August 2021

Abnormal cells that develop into oesophageal cancer – cancer that affects the tube connecting the mouth and stomach – start life as cells of the stomach, according to scientists at the University of Cambridge. Read the original article here>


Read more at: The virologist helping us to stay one step ahead of infectious diseases

The virologist helping us to stay one step ahead of infectious diseases

10 August 2021

An established virologist specialising in the field of HIV drug-resistance, Ravi Gupta pivoted his expertise to address the COVID-19 pandemic. Over the last 18 months his pioneering research has helped us to stay one step ahead of emerging variants. He talks about his career as an infectious disease specialist and, in...


Read more at: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage

Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage

5 August 2021

Cambridge scientists have grown beating heart cells in the lab and shown how they are vulnerable to SARS-CoV-2 infection. In a study published in Communications Biology , they used this system to show that an experimental peptide drug called DX600 can prevent the virus entering the heart cells. Read the original article...


Read more at: Rare genetic variants confer largest increase in type 2 diabetes risk seen to date

Rare genetic variants confer largest increase in type 2 diabetes risk seen to date

7 July 2021

Scientists at the University of Cambridge have identified rare genetic variants – carried by one in 3,000 people – that have a larger impact on the risk of developing type 2 diabetes than any previously identified genetic effect. Read the original article here>


Read more at: Scientists identify 160 new drugs that could be repurposed against COVID-19

Scientists identify 160 new drugs that could be repurposed against COVID-19

30 June 2021

Cambridge scientists have identified 200 approved drugs predicted to work against COVID-19 – of which only 40 are currently being tested in COVID-19 clinical trials. Read the original article here>


Read more at: Upgrading PPE for staff working on COVID-19 wards cut hospital-acquired infections dramatically

Upgrading PPE for staff working on COVID-19 wards cut hospital-acquired infections dramatically

29 June 2021

When Addenbrooke’s Hospital in Cambridge upgraded its face masks for staff working on COVID-19 wards to filtering face piece 3 (FFP3) respirators, it saw a dramatic fall – up to 100% – in hospital-acquired SARS-CoV-2 infections among these staff. Read the original article here>


Read more at: Targeting cellular response to SARS-CoV-2 holds promise as new way to fight infection

Targeting cellular response to SARS-CoV-2 holds promise as new way to fight infection

17 June 2021

A new treatment approach focused on fixing cell damage, rather than fighting the virus directly, is effective against SARS-CoV-2 in lab models. If found safe for human use, this anti-viral treatment would make COVID-19 symptoms milder and speed up recovery times. Read the original article here>